Literature DB >> 24120597

Cord blood serum-based eye drops: the impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels.

Piera Versura1, Marina Buzzi2, Giuseppe Giannaccare1, Marco Grillini1, Adriana Terzi2, Pasqualepaolo Pagliaro2, Emilio C Campos1.   

Abstract

BACKGROUND: Cord blood serum (CBS)-based eye drops are successfully used in corneal epithelial wound healing and are prepared to supply a known amount of epidermal growth factor (EGF). Product standardisation includes expensive EGF dosage in all cord blood (CB) units. The influence of donor obstetric and haematological characteristics on EGF content was evaluated, to exclude unsuitable CBS and pre-select those CB units able to provide the correct EGF supply for healing corneal wounds.
MATERIALS AND METHODS: Data were retrospectively collected from 135 donors included in the Emilia Romagna Cord Blood Bank records. Obstetric characteristics, parity and gestational age of the mother, sex, birth weight and Apgar score of the neonate, placental weight, duration of labour and mode of delivery were considered. Haematological characteristics, CD34+ cell number, and total nucleated cell, white blood cell and platelet counts were recorded. EGF content in CB units was estimated by enzyme-linked immunosorbent assay. Statistical evaluation was performed by Mann-Whitney unpaired and Student's t tests. Correlations between variables were evaluated by using Pearson's (r) or Spearman's (ρ) correlation coefficients.
RESULTS: EGF content was significantly higher in CBS from donors aged <30 years and after vaginal deliveries as compared with scheduled Caesarean sections (1,386±580 vs 1,106±391 pg/mL; P=0.002). EGF content was significantly correlated with duration of labour (r=0.45; P=0.0001), number of CD34+ cells/mL (r=0.3; P=0.002) particularly in vaginal deliveries (r=0.36; P=0.003), mother's age (-0.25; P=0.005), neonate's birth weight (r=0.27; P=0.005), and total nucleated cell (r=0.25; P=0.006), white cell (r=0.29; P=0.001) and platelet (r=0.24; P=0.009) counts. No significant correlations were found between EGF content and parity, gestational age, placental weight, neonate's sex or Apgar scores. DISCUSSION: EGF levels are higher in CB units from younger mothers (<30 years), with longer labour duration (>6 hours), and higher CD34+ cell content (>0.05×10(6)/mL). In order to optimise the preparation and costs of CBS-based eye drops, pre-selection of CB units is recommended.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24120597      PMCID: PMC3934281          DOI: 10.2450/2013.0115-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  28 in total

1.  Evaluation of umbilical cord serum therapy in acute ocular chemical burns.

Authors:  Namrata Sharma; Manik Goel; Thirumurthy Velpandian; Jeewan S Titiyal; Radhika Tandon; Rasik B Vajpayee
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-25       Impact factor: 4.799

2.  Comparison of corneal epitheliotrophic capacity among different human blood-derived preparations.

Authors:  Elizabeth P Shen; Fung-Rong Hu; Shyh-Chyi Lo; Yan-Ming Chen; Yi-Chen Sun; Chung-Tien Lin; Wei-Li Chen
Journal:  Cornea       Date:  2011-02       Impact factor: 2.651

3.  Optimizing umbilical cord blood collection: impact of obstetric factors versus quality of cord blood units.

Authors:  F Mancinelli; A Tamburini; A Spagnoli; C Malerba; G Suppo; R Lasorella; P de Fabritiis; A Calugi
Journal:  Transplant Proc       Date:  2006-05       Impact factor: 1.066

4.  Cesarean section due to fetal distress increases the number of stem cells in umbilical cord blood.

Authors:  Gwendolin Manegold; Sandrine Meyer-Monard; Andre Tichelli; Doris Pauli; Wolfgang Holzgreve; Carolyn Troeger
Journal:  Transfusion       Date:  2008-01-15       Impact factor: 3.157

5.  Umbilical cord blood cells.

Authors:  Jennifer D Newcomb; Alison E Willing; Paul R Sanberg
Journal:  Methods Mol Biol       Date:  2009

Review 6.  Non-haematological uses of cord blood stem cells.

Authors:  David T Harris
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

7.  Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease.

Authors:  K C Yoon; I Y Jeong; S K Im; Y G Park; H J Kim; J Choi
Journal:  Bone Marrow Transplant       Date:  2007-01-08       Impact factor: 5.483

8.  Nerve growth factor, birth outcome and pre-eclampsia.

Authors:  Anitha Kilari; Savita Mehendale; Hemlata Pisal; Tushar Panchanadikar; Anvita Kale; Sadhana Joshi
Journal:  Int J Dev Neurosci       Date:  2010-09-21       Impact factor: 2.457

9.  Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.

Authors:  Kyung-Chul Yoon; In-Cheon You; Seong-Kyu Im; Tae-Sun Jeong; Yeoung-Geol Park; Jin Choi
Journal:  Ophthalmology       Date:  2007-03-26       Impact factor: 12.079

10.  Cord blood revelations: the importance of being a first born girl, big, on time and to a young mother!

Authors:  C P McGuckin; C Basford; K Hanger; S Habibollah; N Forraz
Journal:  Early Hum Dev       Date:  2007-10-17       Impact factor: 2.079

View more
  9 in total

1.  Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops.

Authors:  Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive
Journal:  Int Ophthalmol       Date:  2017-06-15       Impact factor: 2.031

2.  Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops.

Authors:  Piera Versura; Marina Buzzi; Giuseppe Giannaccare; Adriana Terzi; Michela Fresina; Claudio Velati; Emilio C Campos
Journal:  Blood Transfus       Date:  2015-07-09       Impact factor: 3.443

3.  Evaluation of EU legislation on blood: a bioethical point of view.

Authors:  Carlo Petrini
Journal:  J Blood Med       Date:  2017-11-09

Review 4.  Neurotrophic keratitis: current challenges and future prospects.

Authors:  Piera Versura; Giuseppe Giannaccare; Marco Pellegrini; Stefano Sebastiani; Emilio C Campos
Journal:  Eye Brain       Date:  2018-06-28

Review 5.  Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.

Authors:  Federico Bernabei; Matilde Roda; Marina Buzzi; Marco Pellegrini; Giuseppe Giannaccare; Piera Versura
Journal:  J Clin Med       Date:  2019-09-17       Impact factor: 4.241

6.  Impact of blood source and component manufacturing on neurotrophin content and in vitro cell wound healing.

Authors:  Sabrina Valente; Nico Curti; Enrico Giampieri; Vanda Randi; Chiara Donadei; Marina Buzzi; Piera Versura
Journal:  Blood Transfus       Date:  2021-08-03       Impact factor: 5.752

Review 7.  Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis.

Authors:  Maria Rosaria De Pascale; Michele Lanza; Linda Sommese; Claudio Napoli
Journal:  J Ophthalmol       Date:  2015-10-04       Impact factor: 1.909

8.  Topical Treatment with Cord Blood Serum in Glaucoma Patients: A Preliminary Report.

Authors:  Emilio Campos; Piera Versura; Giuseppe Giannaccare; Adriana Terzi; Silvia Bisti; Stefano Di Marco; Marina Buzzi
Journal:  Case Rep Ophthalmol Med       Date:  2018-07-25

9.  Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain.

Authors:  Paolo Rebulla; Sergio Querol; Simonetta Pupella; Daniele Prati; Joaquin Delgadillo; Vincenzo De Angelis
Journal:  Front Cell Dev Biol       Date:  2022-01-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.